BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koudriavtseva T. Thrombotic processes in multiple sclerosis as manifestation of innate immune activation. Front Neurol 2014;5:119. [PMID: 25071707 DOI: 10.3389/fneur.2014.00119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Ziliotto N, Bernardi F, Jakimovski D, Zivadinov R. Coagulation Pathways in Neurological Diseases: Multiple Sclerosis. Front Neurol 2019;10:409. [PMID: 31068896 DOI: 10.3389/fneur.2019.00409] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
2 Ahmed O, Geraldes R, DeLuca GC, Palace J. Multiple sclerosis and the risk of systemic venous thrombosis: A systematic review. Mult Scler Relat Disord 2019;27:424-30. [PMID: 30642566 DOI: 10.1016/j.msard.2018.10.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Koudriavtseva T, Renna R, Plantone D, Mainero C. Demyelinating and thrombotic diseases of the central nervous system: common pathogenic and triggering factors. Front Neurol 2015;6:63. [PMID: 25852641 DOI: 10.3389/fneur.2015.00063] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
4 Koudriavtseva T, Stefanile A, Fiorelli M, Lapucci C, Lorenzano S, Zannino S, Conti L, D'Agosto G, Pimpinelli F, Di Domenico EG, Mandoj C, Giannarelli D, Donzelli S, Blandino G, Salvetti M, Inglese M. Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis. Front Immunol 2020;11:548604. [PMID: 33193314 DOI: 10.3389/fimmu.2020.548604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Plantone D, De Angelis F, Doshi A, Chataway J. Secondary Progressive Multiple Sclerosis: Definition and Measurement. CNS Drugs 2016;30:517-26. [PMID: 27166830 DOI: 10.1007/s40263-016-0340-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
6 Doskas T, Dardiotis E, Vavougios GD, Ntoskas KT, Sionidou P, Vadikolias K. Stroke risk in multiple sclerosis: a critical appraisal of the literature. International Journal of Neuroscience. [DOI: 10.1080/00207454.2022.2056459] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ziliotto N, Baroni M, Straudi S, Manfredini F, Mari R, Menegatti E, Voltan R, Secchiero P, Zamboni P, Basaglia N, Marchetti G, Bernardi F. Coagulation Factor XII Levels and Intrinsic Thrombin Generation in Multiple Sclerosis. Front Neurol 2018;9:245. [PMID: 29731736 DOI: 10.3389/fneur.2018.00245] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
8 Koudriavtseva T, Villani V, Lorenzano S, Giannarelli D, Di Domenico EG, Stefanile A, Maschio M, D'Agosto G, Pimpinelli F, Tanzilli A, Galiè E, Pace A. Neutrophil-to-lymphocyte ratio, Factor VIII and Antithrombin III: inflammatory-clotting biomarkers in glioma. EXCLI J 2021;20:1152-69. [PMID: 34345234 DOI: 10.17179/excli2021-3831] [Reference Citation Analysis]
9 Pazhouhandeh M, Sahraian MA, Siadat SD, Fateh A, Vaziri F, Tabrizi F, Ajorloo F, Arshadi AK, Fatemi E, Piri Gavgani S, Mahboudi F, Rahimi Jamnani F. A systems medicine approach reveals disordered immune system and lipid metabolism in multiple sclerosis patients. Clin Exp Immunol 2018;192:18-32. [PMID: 29194580 DOI: 10.1111/cei.13087] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
10 Jordan KR, Parra-Izquierdo I, Gruber A, Shatzel JJ, Pham P, Sherman LS, McCarty OJT, Verbout NG. Thrombin generation and activity in multiple sclerosis. Metab Brain Dis 2021;36:407-20. [PMID: 33411219 DOI: 10.1007/s11011-020-00652-w] [Reference Citation Analysis]
11 Koudriavtseva T, Plantone D, Renna R. Antiphospholipid antibodies: a possible biomarker of disease activity in multiple sclerosis and neuromyelitis optica spectrum disorders. J Neurol 2014;261:2028-9. [PMID: 25236654 DOI: 10.1007/s00415-014-7506-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
12 Filippidou N, Krashias G, Pericleous C, Rahman A, Ioannou Y, Giles I, Demetriou C, Anatolitou A, Christodoulou C, Pantzaris M, Lambrianides A. The association between IgG and IgM antibodies against cardiolipin, β2-glycoprotein I and Domain I of β2-glycoprotein I with disease profile in patients with multiple sclerosis. Molecular Immunology 2016;75:161-7. [DOI: 10.1016/j.molimm.2016.05.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]